ClinicalTrials.gg
Active, not recruitingNCT04293185Updated Dec 10, 2024

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

A Phase 3 interventional study of bb1111 in Sickle Cell Disease, sponsored by bluebird bio. Active, not recruiting at 9 sites in United States. Open to participants aged 2 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by bluebird bio · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
2 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Planned enrollment
266th of 559
35 · median 31
Started
2020
with 46 others
Phase 3
50 of 733
10 open now
Primary completion
2027-05
later than 74 of 182 live
Registered
493rd of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 266th largest by planned enrollment of the 559 interventional ones that give a count, is one of 47 that started in 2020, is one of 50 in phase 3, reaches primary completion later than 74 of the 182 other live ones, and was the 493rd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a non-randomized, open-label, multi-site, single-dose, Phase 3 study in approximately 35 adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD). The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) using bb1111 (also known as LentiGlobin BB305 Drug Product for SCD).

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
2 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of SCD, with either βS/βS, βS/β0, or βS/β+ genotype.
  • Be ≥2 and ≤50 years of age at time of consent.
  • Weigh a minimum of 6 kg.
  • Have a performance status of ≥60 (≥16 years of age) or a Lansky performance status of ≥60 (\<16 years of age).
  • Be treated and followed for at least the past 24 months prior to in medical center(s) that maintained detailed records on sickle cell disease history.
  • In the setting of appropriate supportive care measures (e.g., pain management plan), have experienced at least 4 protocol-defined VOEs in the 24 months prior to informed consent.
  • Have either experienced HU failure at any point in the past or must have intolerance to HU (intolerance is defined as the patient being unable to continue to take HU per PI judgment).
  • Female and male subjects of agree to use 1 method of highly effective from Screening to at least 6 months after drug product infusion.
  • Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/legal guardian(s).

Exclusion criteria

Exclusion Criteria:

  • Subjects for whom hematopoietic stem cell transplantation (allo-HSCT) is medically appropriate per PI judgment and a willing, human leukocyte antigen (HLA)-matched related hematopoietic stem cell donor is available.
  • Severe cerebral vasculopathy, defined by any history of overt ischemic or hemorrhagic stroke, a history of abnormal transcranial Doppler (TCD) or TCD imaging (TCDI) for subjects ≤ 16 years of age (e.g. TCD velocity >200 cm/sec) requiring ongoing chronic transfusions, a Screening TCD or TCDI velocity > 200 cm/sec (central read), a Screening MRA showing > 50% stenosis or occlusion in the circle of Willis (central read), or a Screening MRA showing the presence of Moyamoya (central read).
  • Positive for presence of type 1 or 2 (HIV-1 or HIV-2), , , human T-lymphotropic virus-1 (HTLV-1), active syphilis.
  • , active bacterial, viral, fungal, or parasitic infection
  • Advanced liver disease, such as

    1. clear evidence of liver cirrhosis, active hepatitis or significant fibrosis (based on MRI or liver )
    2. liver iron concentration ≥15 mg/g unless liver biopsy shows no evidence of cirrhosis, active hepatitis or significant fibrosis
  • Inadequate bone marrow function, as defined by an of \<1×10\^9/L (\<0.5×10\^9/L for subjects on hydroxyurea treatment) or a count \<100×10\^9/L.
  • Any to the use of plerixafor during the mobilization of hematopoietic stem cells and any contraindications to the use of busulfan and any other medicinal products required during the myeloablative conditioning, including to the active substances or to any of the .
  • Patients needing therapeutic anticoagulation treatment during the period of conditioning through platelet engraftment
  • Unable to receive pRBC transfusion.
  • Prior receipt of an allogeneic transplant.
  • Prior receipt of gene therapy.
  • Any prior or current or immunodeficiency disorder, except previously treated, non-life threatening, cured tumors such as squamous cell carcinoma of the skin.
  • Immediate family member with a known or suspected Familial Cancer Syndrome.
  • Female subject is breastfeeding, pregnant or will attempt to become pregnant from Screening to at least 6 months after drug product infusion.
  • Any other condition that would render the subject ineligible for HSCT.
  • Participation in another clinical study with an drug within 30 days of screening.
  • Presence of a chromosomal abnormality or genetic mutation that may put the subject at an increased risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) per Investigator's judgment.
  • Presence of genetic mutations that result in the inactivation of 2 or more α-globin genes
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    bb1111

    Subjects will receive treatment with a single dose of Drug Product manufactured with autologous CD34+ hematopoietic stem cells collected by plerixafor mobilization and apheresis, transduced with BB305 lentiviral vector (LVV) encoding the human beta-A-T87Q globin gene. Plerixafor mobilization and apheresis will also be used for collection of rescue cells.

    Genetic: bb1111

Interventions

  • Geneticbb1111

    Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.

    Also known as: lovotibeglogene autotemcel, lovo-cel, LentiGlobin BB305 Drug Product for SCD, autologous CD34+ cell-enriched population from patients with SCD that contains HSCs transduced with BB305 LVV encoding the βA-T87Q-globin gene, suspended in cryopreservation solution

06

What researchers measure

Primary outcomes

  1. VOE-CR

    Proportion of subjects achieving complete resolution of VOEs between 6 months and 18 months after drug product infusion

    Time frame: 6-18 months post-transplant

Secondary outcomes

  1. sVOE-CR

    Proportion of subjects achieving complete resolution of severe vaso-occlusive events, between 6 months and 18 months after drug product infusion

    Time frame: 6-18 months post-transplant

  2. Proportion of subjects achieving Globin Response

    Globin Response, defined as meeting the following criteria for a continuous period of at least 6 months after drug product infusion: 1. Weighted average HbAT87Q percentage of non-transfused total Hb\* ≥30% AND 2. Weighted average non-transfused total Hb\* increase of ≥3 g/dL compared to baseline total Hb\* OR weighted average non-transfused total Hb\* ≥10 g/dL * non-transfused total Hb is the total g/dL of HbS + HbF + HbA2 + HbAT87Q

    Time frame: 6-24 months post-transplant

  3. Change in the annualized number of VOEs in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent

    Time frame: 1-24 months post-transplant

  4. Change in the annualized number of severe VOEs in the 24 months after drug product infusion compared to the 24 months prior to Informed Consent.

    Time frame: 1-24 months post-transplant

  5. VOE-CR24

    Proportion of subjects achieving complete resolution of VOEs between 6 months and 24 months after drug product infusion

    Time frame: 6-24 months post-transplant

  6. sVOE-CR24

    Proportion of subjects achieving complete resolution of severe VOEs between 6 months and 24 months after drug product infusion

    Time frame: 6-24 months post-transplant

  7. sVOE-75

    Proportion of subjects achieving at least a 75% reduction in annualized severe VOEs in the 24 months after drug product administration compared to the 24 months prior to Informed Consent.

    Time frame: 1-24 months post-transplant

  8. Weighted average non-transfused total Hb

    Time frame: Month 6, 12, 18 and 24 post-transplant

  9. Weighted average HbS percentage of non-transfused total Hb

    Time frame: Month 6, 12, 18 and 24 post-transplant

  10. Weighted average HbS percentage of non-transfused total Hb ≤70%, ≤60%, ≤50%

    Time frame: Month 6, 12, 18 and 24 post-transplant

  11. Weighted average HbAT87Q percentage of non-transfused total Hb

    Time frame: Month 6, 12, 18 and 24 post-transplant

  12. Weighted average non-HbS percentage of non-transfused total Hb

    Time frame: Month 6, 12, 18 and 24 post-transplant

  13. Average and median of non-transfused total Hb

    Time frame: 1-24 months post-transplant

  14. Average and median of HbS percentage of non-transfused total Hb

    Time frame: 1-24 months post-transplant

  15. Average and median of HbAT87Q percentage of non-transfused total Hb

    Time frame: 1-24 months post-transplant

  16. Average and median of non-HbS percentage of non-transfused total Hb

    Time frame: 1-24 months post-transplant

  17. Change from baseline in absolute reticulocyte count

    Time frame: 1-24 months post-transplant

  18. Change from baseline in percent reticulocytes

    Time frame: 1-24 months post-transplant

  19. Change from baseline in percent erythrocytes

    Time frame: 1-24 months post-transplant

  20. Change from baseline in total bilirubin

    Time frame: 1-24 months post-transplant

  21. Change from baseline in haptoglobin

    Time frame: 1-24 months post-transplant

  22. Change from baseline in lactate dehydrogenase

    Time frame: 1-24 months post-transplant

  23. Change from baseline in ferritin

    Time frame: 1-24 months post-transplant

  24. Change from baseline in liver iron content

    Time frame: 1-24 months post-transplant

  25. Change from baseline in cardiac iron content (if assessed at baseline)

    Time frame: 1-24 months post-transplant

  26. Change from baseline in erythropoietin

    Time frame: 1-24 months post-transplant

  27. Change from baseline in serum transferrin receptor

    Time frame: 1 - 24 months post-transplant

  28. Change from baseline in annualized frequency of packed red blood cell (pRBC) transfusions

    Time frame: 6-24 months post-transplant

  29. Change from baseline in annualized volume of pRBC transfusions

    Time frame: 6-24 months post-transplant

  30. Change from baseline in TCD velocity at Month 12 and Month 24 (for subjects ≤ 16 years old at Informed Consent)

    Time frame: Month 12 and Month 24 post-transplant

  31. Change from baseline in meters walked during the 6-minute walk test

    Time frame: 1 - 24 months post-transplant

  32. Change from baseline in annualized number of SCD-related hospital admissions

    Time frame: 1 - 24 months post-transplant

  33. Change from baseline in annualized number of total days hospitalized

    Time frame: 1 - 24 months post-transplant

  34. Change from baseline in patient-reported quality of life, as measured by PROMIS-57 Version 2.1 for subjects ≥ 18 years of age and PROMIS Pediatric Profile/Parent Proxy Profile 49 Version 2.0 for subjects < 18 years of age

    Time frame: 1 - 24 months post-transplant

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: Yes — Bluebird bio is committed to transparency and appropriately de-identified patient-level datasets and supporting documents may be shared upon completion of study participation and following attainment of applicable marketing approvals associated with this study and consistent with criteria established by bluebird bio and/or industry best practices to maintain the privacy of study participants. For enquiries, please contact us at datasharing@bluebirdbio.com.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for May 2027, 87 months after the start.

Of 35 phase 3 interventional studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 61. This study's planned 87 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Mar 3, 2020
StartActual
Feb 14, 2020
Primary completionEst.
May 2027
CompletionEst.
Nov 2027
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04293185
Lead sponsor
bluebird bio
Responsible party
Sponsor
First posted
Mar 3, 2020
Start date
Feb 14, 2020
Primary completion
May 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Dec 10, 2024

Study contacts

Anjulika Chawla, MD, FAAP
study director · bluebird bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion